A detailed history of Jacobs Levy Equity Management, Inc transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 811,512 shares of PSTX stock, worth $2.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
811,512
Previous 927,006 12.46%
Holding current value
$2.6 Million
Previous $2.71 Million 14.26%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.7 - $4.04 $311,833 - $466,595
-115,494 Reduced 12.46%
811,512 $2.32 Million
Q2 2024

Aug 14, 2024

BUY
$2.0 - $3.46 $193,758 - $335,201
96,879 Added 11.67%
927,006 $2.71 Million
Q1 2024

May 15, 2024

BUY
$2.76 - $4.13 $1.08 Million - $1.62 Million
391,801 Added 89.39%
830,127 $2.65 Million
Q4 2023

Feb 14, 2024

BUY
$1.83 - $3.51 $802,136 - $1.54 Million
438,326 New
438,326 $1.47 Million
Q2 2022

Aug 15, 2022

BUY
$1.87 - $5.0 $142,555 - $381,165
76,233 Added 536.4%
90,445 $233,000
Q1 2022

May 16, 2022

SELL
$3.22 - $7.04 $1.01 Million - $2.21 Million
-314,169 Reduced 95.67%
14,212 $64,000
Q4 2021

Feb 14, 2022

SELL
$6.23 - $7.6 $103,187 - $125,878
-16,563 Reduced 4.8%
328,381 $2.24 Million
Q3 2021

Nov 15, 2021

SELL
$7.09 - $10.71 $136,319 - $205,921
-19,227 Reduced 5.28%
344,944 $2.52 Million
Q2 2021

Aug 16, 2021

SELL
$7.96 - $10.07 $164,334 - $207,895
-20,645 Reduced 5.36%
364,171 $3.65 Million
Q1 2021

May 17, 2021

BUY
$8.51 - $11.91 $3.06 Million - $4.28 Million
359,002 Added 1390.73%
384,816 $3.68 Million
Q4 2020

Feb 16, 2021

BUY
$8.29 - $11.7 $213,998 - $302,023
25,814 New
25,814 $283,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $275M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.